Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
EXT-608 by Extend Biosciences for Hypoparathyroidism: Likelihood of Approval
EXT-608 is under clinical development by Extend Biosciences and currently in Phase II for Hypoparathyroidism. According to GlobalData, Phase II...
Data Insights
EXT-608 by Extend Biosciences for Hypoparathyroidism: Likelihood of Approval
EXT-608 is under clinical development by Extend Biosciences and currently in Phase I for Hypoparathyroidism. According to GlobalData, Phase I...